RhoVac Participates in BIO Europe Digital
Sweden's RhoVac Aims To Become An M&A Target :: Scrip
Nyemission i RhoVac AB på Spotlight - Aktier
The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
RhoVac retains international investment bank as advisor for desired RV001 transaction
RhoVac's CEO, Anders Månsson, has tendered his resignation
139/19 – Information regarding the rights issue from RhoVac AB
Market Notice 56/22 - Last day of trading in RhoVac AB's BTU
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial
spotlight_group_logo_cmyk.png
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac AB | Aktiespararna
RhoVac AB will be transferred to Spotlight Stock Market's observation list
RhoVac — Stopping metastasis in its tracks - Edison Group
Technical Analysis | Spotlight
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac AB Share Price | RNS News, Quotes, & Charts |
RhoVac publishes research results prior ASCO's meeting
RhoVac Confirms Forecast – BRaVac Phase IIb study recruitment to close in Quarter 3 2021
RhoVac aktie (RHOVAC) | Alla nyheter, analys, riktkurs… - Börskollen
Market notice 94/22 – RhoVac AB´s financial instruments are moved to the Observation List
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board
